Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Vitamin D Receptor Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VDR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VDR Ligand Binding Domain (LBD) / Full-Length Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. For ligand-binding and co-regulator recruitment assays. |
View VDR Products |
| Gene Delivery | VDR Promise-ORF / Lentivirus Full-length ORF for stable cell lines and transcription reporter assays. |
View VDR Products |
| Benchmark Ab | Anti-VDR Antibody (Sequence of Clinical/Research Benchmarks) Recombinant positive control for western blot, ChIP, and IHC. |
View VDR Products |
| Validator | VDR siRNA Set For knockdown verification in target-specificity assays. |
View VDR Products |
| Related Target A | RXRA (Retinoid X Receptor Alpha) Essential heterodimerization partner for VDR to bind DNA and initiate transcription. |
View RXRA Products |
| Related Target B | CYP24A1 (Cytochrome P450 Family 24 Subfamily A Member 1) The primary enzyme responsible for VDR ligand degradation; key target for overcoming metabolic resistance. |
View CYP24A1 Products |
| Related Target C | TRPV6 (Transient Receptor Potential Vanilloid 6) VDR-regulated calcium channel; critical marker for screening out hypercalcemia-inducing off-target effects. |
View TRPV6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Co-regulator Recruitment Profiling | High-purity recombinant VDR LBD protein with verified sequence identity and high stability in biochemical assays. |
| Heterodimerization Assessment | Validated RXRA partner proteins available for complex reconstitution. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives / Off-Target Effects | Validated siRNA included for specificity checks |
Live VDR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VDR therapeutics is intensifying, with major players shifting focus from traditional systemic agonists to Selective Vitamin D Receptor Modulators (SVDRMs) and tissue-targeted delivery systems. As first-generation therapies reach the clinic, the next wave of R&D is targeting autoimmune diseases, oncology (tumor microenvironment modulation), and metabolic disorders while minimizing the dose-limiting toxicity of hypercalcemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Agonists (SVDRMs) | Leo Pharma, Karo Bio, Pfizer | Psoriasis, Atopic Dermatitis, Osteoporosis | Co-activator recruitment assays (Need high-purity VDR LBD protein) |
| VDR-RXR Heterodimer Modulators | Academic Consortia, Biotech Startups | Oncology (Colorectal, Breast Cancer) | Dimerization and DNA binding assays (Need VDR and RXRA proteins) |
| Gene Therapy / Overexpression | In-house Pharma R&D | Inflammatory Bowel Disease (IBD) | Stable cell line development (Need high-titer VDR Lentiviral Particles) |